22q11.2 Deletion Syndrome
14
5
5
6
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
21.4%
3 terminated out of 14 trials
66.7%
-19.9% vs benchmark
0%
0 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (14)
Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion Syndrome
The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach to Non-invasive Fetal Risk Assessment
Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disorders
Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome (INSPIRE)
Understanding of Psychotic Disorders in Children With 22q11.2DS
Arithmetic Abilities in Children With 22q11.2DS
Neuroprotective Effects of Risperdal on Brain and Cognition in 22q11 Deletion Syndrome
Early Scoliotic Changes in Children at Increased Risk for Scoliosis Development
Effects of Methylphenidate on Brain and Cognition in 22q11 Deletion Syndrome
Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions
Genetic Modifiers for 22q11.2 Syndrome
Social Cognition Training and Cognitive Remediation
Resolution of Primary Immune Defect in 22q11.2 Deletion Syndrome
Cognitive Remediation in 22q11DS